TG Therapeutics CEO: Stock Volatile But Cancer Drugs on Track

Despite the recent volatility in the company's stock, TG Therapeutics cancer drugs are on track for approval and will ultimately fill a niche where old generic chemotherapies have failed, says the company's CEO Michael Weiss. Weiss believes that this specific market will triple over the next 10 to 15 years with the introduction of newer, more effective drugs like the ones being developed by TG. And while there are doubters in the stock, Weiss believes he can repeat the success he enjoyed previously at Keryx, which he grew to a $1 billion company at its peak.

Disclosure: TheStreet's editorial policy prohibits staff editors and reporters from holding positions in any individual stocks.